JAAN BIOTHERAPEUTICS LLC — Department of Health and Human Services SBIR Phase I: NHLBI

Description

PROJECT SUMMARY Ischemic heart disease IHD is the single largest cause of death worldwide A heart attack or myocardial infarction MI results from limitation of coronary blood flow to the heart causing ischemia and irreversible death of cardiomyocytes The ultimate size of an infarct correlates with the degree of deterioration of heart function compromise of contractile reserve and the likelihood of mortality from heart failure HF Prompt restoration of arterial perfusion with thrombolytic and antiplatelet therapy during percutaneous coronary interventions has led to a decline in acute mortality from MI However the prevalence of HF among survivors has been augmented because irreversible cardiomyocyte death results in residual ischemia and myocardial scarring causing left ventricular dysfunction The failure of human adult cardiomyocytes to regenerate themselves endogenously and couple successfully with surviving myocardium following an infarction constitutes a major clinical problem This is compounded by the lack of adjunctive treatments pharmacologic or cellular that can be administered in conjunction with reperfusion to successfully stimulate regeneration of heart muscle Promotion of endogenous cardiomyocyte regeneration in the ischemic infarcted heart with concomitant reduction of scar size would offer a powerful new treatment of this devastating disease and its adverse pathophysiologic consequences Inhibition of a specific combination of four microRNAs miR miR let a and let c is a critical regulator of cardiomyocyte dedifferentiation and heart regeneration in zebrafish The sequences and target proteins of these four microRNAs miRs are conserved in humans In vivo adeno associated virus AAV delivery of inhibitors of these miRs into the hearts of mice with a permanent MI increases cardiomyocyte regeneration which was confirmed by the expression of proliferation and cytokinesis markers scar tissue regression and heart functional improvement JAAN Biotherapeutics L L C has developed an optimized single virus formulation JBT miR that simultaneously expresses inhibitors to miR and let a c Use of this AAV cross packaged into AAV capsids AAV allows for temporal expression cardiac tropism and is non integrative minimizing potential off target side effects JBT miR constitutes an innovative approach for regeneration of human cardiomyocytes The proposed research in Aim of this Phase I study will determine whether JBT miR can regenerate murine heart muscle after a transient minute ischemic injury when administered intravenously either immediately after reperfusion or one week after reperfusion Aim will establish cardiac and tissue distribution of the virus off target histopathology pleiotropic effects metabolic function blood tests and electrophysiological changes Aim is critical to confirm efficacy and timing of delivery of JBT miR to promote cardiomyocyte regeneration Whereas Aim provides information on the safety of the virus These studies are pivotal for future preclinical and clinical study design PROJECT NARRATIVE This proposal aims to develop a therapy that can be given to patients shortly after a heart attack to improve their long term outcome and reduce their transition to heart failure The academic partner has developed mouse models of ischemic heart disease and methods that provide precise three dimensional visualization and quantification of heart damage and function The small business partner has designed and patented an innovative viral delivery approach that regenerates damaged cardiac muscle by reactivating an evolutionary conserved process Together we will determine whether a new therapy JBT miR can feasibly reduce the pathophysiology of ischemic injury in mice when administered intravenously and without inducing side effects This will enable the design of future efficacy and safety toxicology studies allowing clinical development that could improve the long term outcome for patients with ischemic heart disease